Studies conducted by Hang et al and Li et al have determined that CSC expressing CD133 and ABCG2 have decreased overall survival, chemotherapeutic response rates, and increased the rate of relapses in NSCLC patients 37,38. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.